Ultragenyx Pharmaceutical Inc. (RARE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250M 500M 750M Q2 '18: 26.1M Q3 '18: 37.6M Q4 '18: 51.5M Q1 '19: 59M Q2 '19: 70.3M Q3 '19: 84.4M Q4 '19: 103.7M Q1 '20: 121.9M Q2 '20: 159.4M Q3 '20: 215.1M Q4 '20: 271M Q1 '21: 334.1M Q2 '21: 359.4M Q3 '21: 359.6M Q4 '21: 351.4M Q1 '22: 331.9M Q2 '22: 334.3M Q3 '22: 343.4M Q4 '22: 363.3M Q1 '23: 383.9M Q2 '23: 402.9M Q3 '23: 410.2M Q4 '23: 434M Q1 '24: 442.3M Q2 '24: 481.1M Q3 '24: 522.5M Q4 '24: 560M Q1 '25: 590.2M Q2 '25: 610.1M Q3 '25: 630.6M Q4 '25: 673.2M Q1 '26: 670.2M Q2 '26: 717.2M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 25M 50M 75M Q4 '18: 50.3M Q1 '19: 57.6M Q2 '19: 68.3M Q4 '18 Q1 '19 Q2 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '16: -233.6M Q4 '16: -248M Q1 '17: -264.3M Q2 '17: -284.7M Q3 '17: -302.7M Q4 '17: -328.9M Q1 '18: -355.5M Q2 '18: -371.9M Q3 '18: -377.9M Q4 '18: -371.4M Q1 '19: -374.1M Q2 '19: -391.7M Q3 '19: -420.1M Q4 '19: -424.2M Q1 '20: -445.6M Q2 '20: -396.2M Q3 '20: -328.5M Q4 '20: -330.1M Q1 '21: -316M Q2 '21: -335.7M Q3 '21: -375.3M Q4 '21: -381.7M Q1 '22: -411.8M Q2 '22: -470.6M Q3 '22: -605.9M Q4 '22: -648.9M Q1 '23: -666.4M Q2 '23: -672.8M Q3 '23: -592.8M Q4 '23: -569M Q1 '24: -580.2M Q2 '24: -548.6M Q3 '24: -535.5M Q4 '24: -536M Q1 '25: -513.7M Q2 '25: -505.3M Q3 '25: -544.2M Q4 '25: -535.2M Q1 '26: -561.2M Q2 '26: -528.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-750M -500M -250M 0 250M 500M 750M Q3 '16: -229.8M Q4 '16: -245.9M Q1 '17: -261.4M Q2 '17: -277.4M Q3 '17: -291.7M Q4 '17: -302.1M Q1 '18: -203.6M Q2 '18: -183.4M Q3 '18: -191.5M Q4 '18: -197.6M Q1 '19: -324.6M Q2 '19: -371.1M Q3 '19: -396.7M Q4 '19: -402.7M Q1 '20: -425M Q2 '20: -300.5M Q3 '20: -256.4M Q4 '20: -186.6M Q1 '21: -203.7M Q2 '21: -351.4M Q3 '21: -355.6M Q4 '21: -454M Q1 '22: -470.2M Q2 '22: -505.9M Q3 '22: -678M Q4 '22: -707.4M Q1 '23: -719.1M Q2 '23: -720.7M Q3 '23: -635.3M Q4 '23: -607M Q1 '24: -613.7M Q2 '24: -585.5M Q3 '24: -559.3M Q4 '24: -569M Q1 '25: -549.3M Q2 '25: -532.7M Q3 '25: -579.6M Q4 '25: -575M Q1 '26: -609M Q2 '26: -586M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 700K 1.4M 2.1M Q4 '18: 1.1M Q1 '19: 1.4M Q2 '19: 2M Q4 '18 Q1 '19 Q2 '19

Operating Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '16: -153.7M Q4 '16: -161M Q1 '17: -177.3M Q2 '17: -186.5M Q3 '17: -219.7M Q4 '17: -253.8M Q1 '18: -282.1M Q2 '18: -309.4M Q3 '18: -316.5M Q4 '18: -290.6M Q1 '19: -296.9M Q2 '19: -309.8M Q3 '19: -329.2M Q4 '19: -345.4M Q1 '20: -344.8M Q2 '20: -168.3M Q3 '20: -141.8M Q4 '20: -132.2M Q1 '21: -196.4M Q2 '21: -349.1M Q3 '21: -346.8M Q4 '21: -338.7M Q1 '22: -296.9M Q2 '22: -308.8M Q3 '22: -344.5M Q4 '22: -380.5M Q1 '23: -419.8M Q2 '23: -458.7M Q3 '23: -481.2M Q4 '23: -475M Q1 '24: -508.9M Q2 '24: -469.7M Q3 '24: -418.8M Q4 '24: -414M Q1 '25: -389.3M Q2 '25: -421.3M Q3 '25: -445.5M Q4 '25: -466M Q1 '26: -497M Q2 '26: -485M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-600M -400M -200M 0 200M 400M 600M Q3 '16: -165.2M Q4 '16: -171.2M Q1 '17: -186.5M Q2 '17: -191M Q3 '17: -222.3M Q4 '17: -256.6M Q1 '18: -284.9M Q2 '18: -313.2M Q3 '18: -320.3M Q4 '18: -294.6M Q1 '19: -303.5M Q2 '19: -320.4M Q3 '19: -343.7M Q4 '19: -370.2M Q1 '20: -380.6M Q2 '20: -203.1M Q3 '20: -175.3M Q4 '20: -176.1M Q1 '21: -242.6M Q2 '21: -411.3M Q3 '21: -425.8M Q4 '21: -411.8M Q1 '22: -385.7M Q2 '22: -408.5M Q3 '22: -449.7M Q4 '22: -496.6M Q1 '23: -528.8M Q2 '23: -550.7M Q3 '23: -550.9M Q4 '23: -519M Q1 '24: -531M Q2 '24: -479.9M Q3 '24: -427M Q4 '24: -421M Q1 '25: -394.1M Q2 '25: -427.1M Q3 '25: -450.7M Q4 '25: -472M Q1 '26: -503M Q2 '26: -489M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '13: 3.5M Q2 '13: 3.5M Q3 '13: 3.6M Q1 '14: 21.6M Q2 '14: 30.1M Q3 '14: 31.6M Q1 '15: 34M Q2 '15: 35.9M Q1 '17: 41.8M Q1 '18: 49.1M Q1 '19: 53.2M Q2 '19: 57.5M Q2 '20: 61.1M Q2 '21: 67.6M Q3 '21: 67.9M Q1 '22: 69.5M Q2 '22: 69.9M Q3 '22: 70.1M Q1 '23: 70.4M Q2 '23: 70.9M Q3 '23: 71.7M Q1 '24: 84.3M Q2 '24: 86.6M Q3 '24: 95.5M Q1 '25: 96.3M Q2 '25: 98.5M Q3 '25: 99.8M Q1 '26: 100.6M Q2 '26: 101.9M Q1 '13 Q2 '14 Q1 '17 Q2 '20 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q3 '16: -5.87 Q4 '16: -6.20 Q1 '17: -6.48 Q2 '17: -6.74 Q3 '17: -6.97 Q4 '17: -7.11 Q1 '18: -4.86 Q2 '18: -4.20 Q3 '18: -4.07 Q4 '18: -3.91 Q1 '19: -6.35 Q2 '19: -7.01 Q3 '19: -7.23 Q4 '19: -7.12 Q1 '20: -7.35 Q2 '20: -5.22 Q3 '20: -4.39 Q4 '20: -3.14 Q1 '21: -3.12 Q2 '21: -5.34 Q3 '21: -5.29 Q4 '21: -6.71 Q1 '22: -6.87 Q2 '22: -7.32 Q3 '22: -9.74 Q4 '22: -10.11 Q1 '23: -10.25 Q2 '23: -10.24 Q3 '23: -8.97 Q4 '23: -8.25 Q1 '24: -7.95 Q2 '24: -7.22 Q3 '24: -6.39 Q4 '24: -6.33 Q1 '25: -5.87 Q2 '25: -5.52 Q3 '25: -5.93 Q4 '25: -5.83 Q1 '26: -6.10 Q2 '26: -5.83 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.